Subjects - Finance

Obtaining credit from suppliers and banks in the form of a credit card is an easy form of

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

short-term finance. It can also be the cheapest form of finance. You are, effectively, usi

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

g other people’s money to finance your business although no interest or other charges are

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

payable. The terms of such credit can vary widely from a few weeks up to many months and w

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

ll depend, in many cases, upon the particular type of business that you operate.

It must

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

e stressed, however, that you must not abuse your creditors. As with a bank overdraft, the

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

facility can be just as easily withdrawn as it can be granted. Your creditors can also pe

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

alize you if you do not pay them on time. They will be entitled to charge you interest at

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

penal rates.

If you are considering purchasing any form of fixed asset, for example a pla

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

t and machinery, you must obtain long term finance. In addition, it is prudent to obtain t

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

at finance on repayment terms linked to the likely life of an asset. As an example, if you

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

were purchasing an asset with a working life of, say, three years, it would be prudent to

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

repay the necessary finance over the same term. In most cases the lender will indeed insis

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

t upon this. It would be futile them lending you money over ten years for an asset that wi

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

l only last for three years.

Business credit is also available from a wide variety of sou

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

ces and indeed on a wide range of terms and conditions. Some are secured on assets of one

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

kind or another and some are available on an unsecured basis. As with all forms of finance

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

you need to know and understand the exact conditions under which credit is being made ava

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

ilable. One thing to look out for is early repayment penalties. Even if you do have the me

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

ns to repay the credit early it could cost you extra in terms of a fee or penalty interest

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.subjects.org.ua/article/92222/subjects-Small-Business-Credit-Cards.html">Small Business Credit Cards</a>

BB link (for phorums):
[url=http://www.subjects.org.ua/article/92222/subjects-Small-Business-Credit-Cards.html]Small Business Credit Cards[/url]

The appropriate signage on the advertising balloon will generate a sentimental bonding with the consumers.

Small business start-up need not cost the earth and you can approach it from a number of directions.

Asia has seen a number of businesses make a presence for themselves starting from just having a website in the virtual world. As more and more of Asia obtains broadband, 3G and even WiMax access, the online market increases and more and more people recognise the internet's potential as a cheap and wide reaching entry point for business.

Tags

Links

Subjects - Small Business Credit Cards

Related Articles: